What is the correct HCPCS code for Cystografin® (diatrizoate meglumine injection USP 30%). We had been using Q9963 but are receiving denials stating that the national drug code (NDC) does not match our code.
The correct code for Cystografin® (diatrizoate meglumine injection USP 30%) is Q9958—high osmolar contrast material (HOCM), up to 149 mg/mL iodine concentration, per mL. Gastrografin® (diatrizoate meglumine and diatrizoate sodium solution USP) is reported with Q9963—HOCM, 350–399 mg/mL iodine concentration, per mL.
Cystografin® (diatrizoate meglumine injection USP 30%)
Indications and Usage:
Cystografin-Dilute and Cystografin are indicated for retrograde cystourethrography and are not intended for intravascular injection.
IMPORTANT SAFETY INFORMATION:
Severe sensitivity reactions are more likely to occur in patients with a history of bronchial asthma, significant allergies, or previous reactions to contrast agents.
A history of sensitivity to iodine per se or to other contrast agents is not an absolute contraindication to the use of diatrizoate meglumine, but calls for extreme caution in administration.
Please see full Prescribing Information
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Cystografin is manufactured for Bracco Diagnostics Inc., Monroe Township, NJ 08831, by Patheon Italia S.p.A., Ferentino (Italy).
Cystografin is a registered trademark of Bracco Diagnostics Inc.